Post by Pedersen & Partners

Evolving pharma talent needs in a global market Pedersen & Partners’ Life Sciences & Healthcare Practice Group recently hosted a session examining global shifts in the pharmaceutical value chain—from discovery to manufacturing—and their impact on executive talent strategies. Moderated by Michael Buckley, Client Partner at Pedersen & Partners, the discussion featured Sarah Dolman, Partner at Recon Strategy. Key insights included: - A continued migration of drug discovery and clinical trials to Asia, driven by talent costs, patient diversity, and regulatory flexibility. - The limitations of U.S. reshoring policies due to long facility build times and STEM talent shortages. - Rising demand for leaders with on-the-ground experience in Asia, regulatory acumen, and global supply chain expertise. - Increasing complexity in drug modalities—particularly in Cell & Gene Therapies (CGT)—requiring adaptive leadership in manufacturing and commercialization. As Ms. Dolman stated, “You need people who understand what it’s like to conduct research in different regions and manage production across borders.” For global pharma companies, building leadership teams aligned with evolving technical and geographic needs is no longer optional—it’s strategic. Read the full article below for a deeper look at how executive talent is shaping the next chapter of pharmaceutical innovation. #PedersenAndPartners #ExecutiveSearch #LifeSciences #Leadership #Pharma #ClinicalDevelopment #GlobalTalent